<DOC>
	<DOCNO>NCT01951157</DOCNO>
	<brief_summary>A clinical study lurbinectedin ( PM01183 ) alone combination gemcitabine comparison docetaxel treatment unresectable non-small cell lung cancer ( NSCLC ) patient</brief_summary>
	<brief_title>A Clinical Study Three-arm Lurbinectedin ( PM01183 ) Alone Combination With Gemcitabine Control Arm With Docetaxel Second Line Treatment Non-Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description>A randomized-controlled , three-arm , phase II study lurbinectedin ( PM01183 ) alone combination gemcitabine control arm docetaxel second-line treatment unresectable non-small cell lung cancer ( NSCLC ) patient evaluate antitumor activity progression-free survival four month ( PFS4 ) PM01183 alone combination gemcitabine use single agent docetaxel reference control arm current standard care analyze overall survival ( OS ) , overall survival rate 1-year ( OS12 ) , duration response ( DR ) , antitumor activity , response rate ( RR ) , safety efficacy profile PM01183 alone combination gemcitabine , preliminary compare docetaxel , patient ' quality life ( QoL ) , pharmacokinetics ( PK ) PM01183 , pharmacokinetic/pharmacodynamic ( PK/PD ) correlation pharmacogenomics ( PGx ) explore potential correlation clinical outcome molecular parameter find tumor blood sample</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm unresectable NSCLC Patients must fail one prior line CTbased therapy unresectable disease Age 18 75 year Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 Adequate hematological , renal , metabolic hepatic function At least three week since last prior therapy , least four week since completion prior radiotherapy Negative pregnancy test premenopausal woman Concomitant diseases/conditions unstable angina , myocardial infarction , symptomatic congestive heart failure asymptomatic leave ventricular ejection fraction ( LVEF ) ≤ 50 % , dyspnea , infection human immunodeficiency virus ( HIV ) , active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection , active uncontrolled infection , pleural pericardial effusion , myopathy , limitation patient 's ability comply treatment followup protocol , major illness Histological feature neuroendocrine bronchioalveolar differentiation . Unknown epidermal growth factor receptor ( EGFR ) mutation status previously know EGFR mutate status patient adenocarcinoma . Prior concurrent invasive malignant disease , unless complete remission three year . Significant cancerrelated weight loss ( ≥10 % ) within four week prior treatment start Prior treatment docetaxelcontaining therapy Symptomatic , steroidrequiring progressive central nervous system ( CNS ) involvement Paraneoplastic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>